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Abstract
Background: The research community has a mandate to discover effective treatments for neurodegenerative
disorders. The ethics landscape surrounding this mandate is in a constant state of flux, and ongoing challenges
place ever greater demands on investigators to be accountable to the public and to answer questions about the
implications of their work for health care, society, and policy.
Methods: We surveyed US-based investigators involved in neurodegenerative diseases research about how they
value ethics-related issues, what motivates them to give consideration to those issues, and the barriers to doing so.
Using the NIH CRISP database we identified 1,034 researchers with relevant, active grants and invited them to
complete an online questionnaire. We received 193 responses. We used exploratory factor analysis to transform
individual survey questions into a smaller set of factors, and linear regression to understand the effect of key
variables of interest on the factor scores.
Results: Ethics-related issues clustered into two groups: research ethics and external influences. Heads of research
groups viewed issues of research ethics to be more important than the other respondents. Concern about external
influences was related to overall interest in ethics. Motivators clustered into five groups: ensuring public
understanding, external forces, requirements, values, and press and public. Heads of research groups were more
motivated to ensure public understanding of research than the other respondents. Barriers clustered into four
groups: lack of resources, administrative burden, relevance to the research, and lack of interest. Perceived lack of
ethics resources was a particular barrier for investigators working in drug discovery.
Conclusions: The data suggest that senior level neuroscientists working in the field of neurodegeneration (ND),
and drug discovery specifically, are motivated to consider ethics issues related to their work, but the perceived lack
of ethics resources thwarts their efforts. With bioethics centres at more than 50% of the institutions at which these
respondents reside, the neuroscience and bioethics communities appear to be disconnected. Dedicated ethical,
legal and social implications (ELSI) programs, such as those fully integrated into genetics and regenerative
medicine, provide models for achieving meaningful partnerships not yet adequately realized for scholars and
trainees interested in drug discovery for ND.
Background
Neurodegenerative disease is an umbrella term for ill-
nesses caused by the progressive loss of neurons and
their associated functions. This category of diseases
includes well known disorders such as Alzheimer’sd i s -
ease, Parkinson’s disease and multiple sclerosis, as well
as less prevalent diseases such as amyotrophic lateral
sclerosis (ALS) and Huntington’s disease. The dramatic
and debilitating nature of these diseases, the rise in pre-
valence associated with an aging population, and the
general absence of effective treatments [1,2] place them
increasingly in the public eye [3]. Despite the failure to
discover disease-modifying treatments for most neuro-
degenerative diseases, the neurobiology research com-
munity has in recent years made important advances in
the understanding of the root causes of these disorders
and possible therapeutic directions [4,5]. There are
more active clinical trials ongoing than ever before and
many investigators are optimistic that new preventive
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ade [6,7]. As research progresses, public and stakeholder
expectations about technology and drug discovery will
inevitably intermingle witht h o s eo ft h en e u r o s c i e n c e
community and generate a variety of ethical issues. It is
imperative, therefore, that the societal concerns sur-
rounding potential implications of new findings be inte-
grated into the earliest stages of research. The very
nature of neurodegenerative diseases, including their
slow but unstoppable progression, the vulnerability of
the patient populations, concerns over genetic testing
and other diagnostic tools, the prospect that drugs may
be used to enhance cognitive function, and the myriad
of decisions along the path from bench to bedside
makes this field of neuroscience research especially vul-
nerable to a broad spectrum of ethical issues [8].
Unfortunately, research ethics are commonly misun-
derstood to be synonymous with administrative burdens
rather than understood as a commitment to the moral
implications of research [9]. Regulatory requirements
poorly aligned to the specific needs of researchers have
undermined efforts to integrate ethics into the research
process itself. As a result, a significant gap has emerged
between laboratory neuroscience research and the socie-
tal impact of that research [10].
A growing body of literature addresses the need for
neuroscientists to identify and examine the societal
implications of their research [11-13]. The relatively
new field of neuroethics, at the intersection of biomedi-
cal ethics and neuroscience, is aimed at assessing the
ethical, legal and social policy implications of research,
and is becoming increasingly visible on the international
neuroscience scene [14]. As neuroscience plays an
increasingly significant role in society, prompting new
understandings of people as social and moral beings
alongside discoveries of the failures and vulnerabilities
of the nervous system, neuroscientists must engage in a
discussion of their science and the implications of their
work. In the present study, we have characterized the
motivators, barriers and priorities for integrating ethics
in a cross-section of principal investigators (PIs), faculty
members, students and professional staff whose work
specifically involves research in neurodegeneration.
Methods
Using the NIH CRISP database, a searchable database of
federally funded research grants of the US-based
National Institutes of Health (NIH), and the RePORTER
query tool, we identified 1,034 researchers who held
active grants with project descriptions containing the
key word string “neurodegen*”. In order to characterize
the most current research activity, we restricted the
search to grants awarded between 2007 and 2009. We
invited researchers based in the United States who met
these criteria to participate in an online survey.
Researchers received their invitation by email and were
asked to forward the invitation to students, postdoctoral
fellows and staff on their research teams. Participation
was anonymous and voluntary. All required approvals
for this study were obtained from the University of Brit-
ish Columbia Behavioural Research Ethics Board.
The online survey contained 25 open and close-ended
questions organized into three sections: I. Ethics in neu-
rodegenerative disease research, II. Motivators and bar-
riers, and III. Current research and background (see
Supplementary material). The questions were aimed at
characterizing the importance of ethics issues research-
ers encounter in their work, as well as both motivators
and barriers to the inclusion of ethics into neurodegen-
erative disease research. The identification of factors
was guided by prior empirical work on ethics in neuroi-
maging [15] and finalized in consultation with members
of our research team. Answers were either multiple
choice or based on a five-point Likert scale, and respon-
dents were encouraged to add free-text narrative con-
tent to augment their answers.
To better understand the structure of our data set, we
applied exploratory factor analysis to the survey data.
This strategy pares down the original large set of survey
items into a smaller set of factors, enabling a meaningful
interpretation of results. We used exploratory factor
analysis with a varimax rotation to ensure that each
individual factor can be described by a linear combina-
tion of a few functions and analyzed the data separately
for each of three categories of ethics-related items: prio-
rities (issues), motivators and barriers. For each cate-
gory, we retained all factors with a corresponding
eigenvalue greater than 1. This process ensures adher-
ence to the Kaiser rule and the appropriate selection of
a number of factors that is less than the number needed
for perfect reconstruction. We determined sampling
adequacy using the Kaiser-Meyer-Olkin (KMO) test to
assess the magnitude of partial correlations among vari-
ables. For each of the three categories, the KMO test led
to a value greater than 0.8; 0.3 greater than the 0.5
required for satisfactory testing. We additionally used
Bartlett’s method to obtain unbiased estimates of the
factor scores for each respondent. These scores were
computed as a weighted sum of the original variables. In
order to understand the effects of the variables of inter-
est on factor scores, we applied a linear regression
model with factor scores as independent variables and
variables of interest as predictors.
Results
Demographics of the study population
One hundred and ninety three (193) neuroscientists
responded to the survey (see Table 1); 62% (119)
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between <30 (n = 12, 6%), 31-50 (n = 108, 56%) and
51 and over (n = 65, 34%). A majority of respondents (n
= 154, 80%) were at the faculty level. Others were grad-
uate or medical students (n = 17, 9%), postdoctoral
fellows (n = 10, 5%) and research staff (n = 5, 3%). A
majority of respondents had attained a PhD and/or an
MD degree (n = 174, 90%), n = 10 (5%) held a BA or
BS equivalent, and n = 7 (4%) held with an MA or MS
equivalent. 158 (82%) respondents described themselves
as the head of their research group.
Half of the respondent pool indicated that they carried
out drug discovery research (50%, n = 97), 25% (n = 48)
regenerative medicine research, and 41% (n = 80) classi-
fied their type of research as “other” (for example,
mechanism of disease and biomarker discovery).
R e s p o n d e n t sh a dt h eo p p o r t u n i t yt os e l e c tm o r et h a n
one type of research.
Participants identified their research subjects as
healthy adults (19%, n = 37), adults with neurodegenera-
tive diseases (33%, n = 64), non-human primates (38%,
n = 74), other animals (69%, n = 134), or other (for
example, cell culture; 83%, n = 161). Disease focus was
Alzheimer’s (51%, n = 98), Parkinson’s( 2 6 % ,n=5 1 ) ,
Huntington’s (20%, n = 38), ALS (17%, n = 32), multiple
sclerosis (7%, n = 13), and a range of others (37%, n = 71)
(e.g., frontotemporal dementia, prion diseases).
Ethics-related issues
Exploratory factor analysis revealed that ethics-related
issues grouped together under two major factors (Table
2): research ethics (accounting for 36.5% of the variance)
and external influences (accounting for 23% of the var-
iance). The research ethics factor included subject confi-
dentiality (loading of 0.98), privacy (loading of 0.96), and
obtaining informed consent (loading of 0.90). The sec-
ond factor, external influences, included government
and public research sponsors (loading of 0.69) and the
influence of industry sponsorship on the direction and
the topic of the research (loading of 0.67). Regression
analysis demonstrated that participants in different
research roles attributed different levels of importance
to ethical issues: heads of research groups (n = 158)
viewed issues surrounding research ethics to be signifi-
cantly more important than the other respondents
(p = 0.01) (Table 3). We also found that overall interest
in ethics had the highest effect on concerns about exter-
nal influences (p < 0.01).
Open-ended comments suggested that communication
of results represents an additional ethical concern in
neurodegenerative disease research. One investigator
commented on science communication in the media:
“Media usually provide uneducated information to (the)
public” [Respondent #32]. In terms of disseminating
results specifically to stakeholders, another researcher
commented on the difficulty of assessing what, when
and how to disclose research results to subjects: “Patern-
alism in withholding versus difficulty (in) accurately
presenting scientific uncertainty” [Respondent #45]. Sev-
eral researchers (n = 21) commented on issues of ethics
in animal care: “(...) the ethical care and use of animals
is important” [Respondent #21]. Open-ended narrative
responses also indicated that conflict of interest repre-
sents an ethical issue in the field of neurodegenerative
research, but opinions about this varied. For example,
one respondent indicated that the “...pendulum has now
swung too far at some academic institutions on conflict
of interest rules. We must now anticipate a year in
advance what might possibly maybe lead to a financial
interest.” [Respondent #11]. Another wrote an
opinion to the contrary, on the issue of “authors not
adequately disclosing potential conflict of interests”
[Respondent #150].
Ethics-related motivators
Ethics-related motivators grouped under five factors
(Table 2). The first, ensuring public understanding
Table 1 Demographics of study population.
Age N (%) Research Area N (%)
<30 12 (6%) Drug discovery 97 (50%)
31-50 108
(56%)
Other (e.g., basic
research)
80 (41%)
51+ 65 (34%) Regenerative medicine 48 (25%)
Gender Research Focus
Male 119
(62%)
Other (e.g., cell culture) 161
(83%)
Female 70 (36%) Other animals 134
(69%)
Professional Level Non-human primates 74 (38%)
Faculty 154
(80%)
Adults with ND disease 64 (33%)
Graduate or Medical
Student
17 (9%) Healthy adults 37 (19%)
Post-doctoral Fellow 10 (5%) Disease Focus
Research Staff 5 (3%) Alzheimer’s 98 (51%)
Highest Degree
Attained
Other 71 (37%)
PhD and/or MD 174
(90%)
Parkinson’s 51 (26%)
BA, BS or equivalent 10 (5%) Huntington’s 38 (20%)
MA, MS or equivalent 7 (4%) ALS 32 (17%)
Head of Research
Group
MS 13 (7%)
Yes 158
(82%)
No 33 (17%)
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Domain Clusters of Factors % of
Variance
Cumulative % of
Variance
Factor Description Factor
Loadings
Ethics Related
Issues
Traditional Research
Ethics
36.5% 36.5% Recruiting subjects representing vulnerable
populations (a)
0.71
Unrealistic expectations about benefits of the research
by subjects (b)
0.65
Subject confidentiality (c) 0.98
Privacy of subjects (d) 0.96
Obtaining informed consent (e) 0.90
Equal access to research for all eligible subjects (f) 0.77
Safety of the method in use (h) 0.62
Clinical findings detected unexpectedly (i) 0.69
External Influences 22.7% 59.2% Commercial conflict of interest (e.g., timing of
technology roll out) (k)
0.63
Priorities of government/public research sponsors (l) 0.69
Influence of industry sponsorship on direction and
topics (m)
0.67
Opinion of media and stakeholders (n) 0.63
Opinion of colleagues (o) 0.52
Effect of patents on publication and release of data
(p)
0.66
Motivators Ensuring Public
Understanding
15.9% 15.9% Mitigating false hopes or expectations by subjects (m) 0.77
Better informed public and policies (n) 0.75
Patients’ right to be informed about neuroscience
advances (o)
0.92
External Forces 14.6% 30.5% Professional advancement (d) 0.78
Institutional encouragement (e) 0.50
Chance of publication success (f) 0.78
Positive perception by clinicians (g) 0.59
Requirements 13.0% 43.5% Institutional encouragement (e) 0.55
Requirement by the institution where you work (h) 0.99
Requirement by research sponsors (i) 0.69
Values 10.5% 54.0% Personal values/seems like the right thing to do (a) 0.83
Good citizenship (c) 0.59
Press and Public 8.7% 62.7% Coverage in the press (k) 0.53
Positive public perception (l) 0.77
Barriers Resources 19.3% 19.3% Lack of relevant ethics resources (f) 0.92
Lack of access to colleagues with ethics expertise (g) 0.64
Burden 17.4% 36.7% Increased administrative work (a) 0.72
Lack of time (e) 0.72
Concern 15.7% 52.4% Ethics is not a relevant or effective tool for my field of
research (b)
0.56
Not your job (c) 0.85
Interest 14.8% 67.2% Lack of individual interest in ethics (h) 0.74
Lack of interest in ethics among neuroscience
colleagues (i)
0.67
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son’s right to be informed about neuroscience advances
(loading of 0.94) and mitigating false hopes or expecta-
tions by research subjects (loading of 0.77). The second
factor, external forces (14.6% of the variance), included
the motivators of professional advancement (loading of
0.78), chance of publication success (loading of 0.78),
and institutional encouragement (loading of 0.5). The
third factor, requirements (13% of the variance),
included obligations to the research institution (loading
of 0.99) and to research sponsors (loading of 0.69). The
fourth factor, values (10.5% of the variance), included
items such as personal values, and the feeling that being
concerned with ethics is “the right thing to do” (loading
of 0.83). The fifth and final factor was press and public
(8.7% of the variance), and included motivators related
to coverage in the press (loading of 0.53) and positive
public perception (loading of 0.77).
Regression analysis highlights an important and signif-
icant effect for professional seniority: heads of research
groups were more motivated to ensure public under-
standing of their research than the other respondents
(p < 0.01) (Table 3). On this same factor of public
understanding of research, we noted that female
researchers rated the importance of matters of public
understanding of research more highly than male
researchers (p = 0.02). Other motivators included both
factors that tie in with public opinion, such as “Increase
in donations” [Respondent #29] as well as factors that
tie in with the implications of the research for society,
such as “Influence on legal developments and regula-
tions” [Respondent #140]. Two respondents also high-
lighted a personal motivation to consider ethics in
research: “... own dedication to trying to cure diseases”
[Respondent #152].
Ethics-related barriers
Barriers to the consideration of ethics in neurodegenera-
tive disease research grouped under four factors:
resources (lack of resources and expertise, accounting
Table 3 Linear regression model: Effect of variables of interest on factor scores.
Covariates
Gender Subjects Research
Type
Head of
Research
Group
Position Interest in
Ethics
Ethics
Consultation
Research
Goal
Female Non-
Human
Animals
Other
(e.g., cell
culture)
Basic Yes Associate
Prof/Assistant
Prof
Postdoc/
Grad
Student
Highly
Interested
Professional Drug
Discovery
Factors
Issues
Traditional
research ethics
-0.05
(p = 0.78)
-0.32
(p = 0.09)
-0.14
(p = 0.67)
-0.06
(p = 0.76)
0.04
(p = 0.94)
0.47
(p < 0.01)
-0.22
(p = 0.70)
0.15
(p = 0.36)
0.39
(p < 0.05)
-0.00
(p = 0.99)
External forces -0.30
(p = 0.13)
0.17
(p = 0.41)
-0.02
(p = 0.96)
-0.23
(p = 0.32)
0.72
(p = 0.19)
-0.25
(p = 0.22)
0.44
(p = 0.49)
0.64
(p < 0.01)
-0.27
(p = 0.17)
0.15
(p = 0.43)
Motivators
Ensuring public
understanding
0.55
(p < 0.01)
-0.36
(p = 0.06)
-0.67
(p < 0.05)
-0.03
(p = 0.87)
0.84
(p = 0.07)
0.14
(p = 0.44)
0.57
(p = 0.30)
0.20
(p = 0.24)
0.24
(p = 0.18)
0.26
(p = 0.13)
External forces -0.11
(p = 0.58)
-0.01
(p = 0.97)
-0.08
(p = 0.83)
0.31
(p = 0.22)
-0.05
(p = 0.93)
0.36
(p = 0.10)
0.56
(p = 0.36)
0.05
(p = 0.79)
0.03
(p = 0.89)
0.03
(p = 0.88)
Requirements -0.07
(p = 0.70)
-0.15
(p = 0.41)
0.01
(p = 0.97)
0.19
(p = 0.37)
-0.87
(p = 0.06)
0.29
(p = 0.12)
-0.36
(p = 0.51)
-0.06
(p = 0.72)
0.24
(p = 0.19)
-0.00
(p = 0.99)
Values 0.15
(p = 0.44)
0.14
(p = 0.53)
0.17
(p = 0.66)
-0.13
(p = 0.59)
-0.54
(p = 0.31)
0.01
(p = 0.96)
-0.54
(p = 0.39)
0.41
(p < 0.05)
0.06
(p = 0.78)
-0.15
(p = 0.45)
Press and
public
-0.15
(p = 0.46)
0.10
(p = 0.66)
-1.02
(p < 0.01)
-0.21
(p = 0.39)
0.17
(p = 0.75)
-0.18
(p = 0.40)
0.18
(p = 0.78)
-0.00
(p = 0.99)
0.14
(p = 0.51)
-0.02
(p = 0.91)
Barriers
Resources 0.07
(p = 0.72)
-0.18
(p = 0.35)
-0.19
(p = 0.60)
0.11
(p = 0.59)
-0.01
(p = 0.99)
-0.22
(p = 0.25)
0.20
(p = 0.72)
0.24
(p = 0.15)
0.20
(p = 0.27)
0.34
(p = 0.06)
Burden -0.12
(p = 0.57)
-0.52
(p < 0.05)
-0.48
(p = 0.27)
0.11
(p = 0.65)
-0.10
(p = 0.85)
-0.05
(p = 0.83)
-0.54
(p = 0.41)
-0.12
(p = 0.55)
0.22
(p = 0.31)
0.02
(p = 0.92)
Concern -0.57
(p < 0.01)
0.48
(p < 0.05)
0.21
(p = 0.59)
0.09
(p = 0.69)
-0.39
(p = 0.43)
0.09
(p = 0.65)
-0.80
(p = 0.18)
-0.35
(p = 0.06)
-0.54
(p < 0.01)
0.16
(p = 0.41)
Interest -0.13
(p = 0.56)
0.05
(p = 0.84)
0.05
(p = 0.90)
0.07
(p = 0.80)
0.72
(p = 0.21)
0.31
(p = 0.17)
0.78
(p = 0.25)
-0.33
(p = 0.11)
0.13
(p = 0.55)
0.16
(p = 0.46)
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increased administrative work; 17.4% of the variance),
concern (ethics are not relevant to the research; 15.7% of
the variance) and interest (lack of interest in ethics from
researcher and colleagues; 14.5% of the variance). A sali-
ent significant finding from the regression analysis with
these factors is that a perceived lack of ethics resources
is a barrier for investigators working in the area of drug
discovery (p < 0.05). The open-ended comments about
ethics-related barriers contributed by respondents spoke
to both the perceived fundamental nature of bioethics,
as one respondent wrote: “Teaching bioethics sometimes
seems like teaching right from wrong” [Respondent
#122] as well as to the practical implications of incor-
porating ethics into research: “(There is a) lack of
understanding by IRB (...) members regarding practical
limitations and time tables that impact research”
[Respondent #131].
Discussion
The data presented here suggest that senior level neu-
roscientists working in the field of neurodegenerative
diseases are motivated to consider ethics issues related
to their work. In addition, these researchers are moti-
vated to ensure public understanding of their research.
However for researchers specifically in the area of drug
discovery, we found that a perceived lack of ethics
resources is a significant barrier to pursuing these inter-
ests and goals.
These findings closely mirror those of a related study
by our group carried out in the field of neuroimaging
[15]. Data from that study and others suggest that
researchers see ethics as complex, overregulated, and
overly time consuming [15,16]. However, considerable
differences also exist between our neurodegeneration
research study and the neuroimaging study. Neuroima-
ging trainees rate indifference as a significant barrier, as
well as a lack of ethics resources. In contrast, we find
that in neurodegeneration research, the lack of ethics
resources acts as a barrier for researchers in drug dis-
covery regardless of professional level. Similarly, gender
effects were present in both cohorts of researchers but
differ in valence. The data from the present study sug-
gest that female researchers rate matters of public
understanding of research more highly than male
researchers. In the neuroimaging study, female research-
ers rated issues such as recruitment, confidentiality and
privacy of human subjects more highly than male
researchers, tended to value trust and reciprocity more
than male researchers, and considered indifference to be
less of a barrier than the male researchers. There we
speculated that the source of the effect may be asso-
ciated with the leadership and organizational skills of
women that underscore the importance of positive
group dynamics and mutual respect [17]. This is expla-
nation may apply to the present results as well, although
more study of this phenomenon is clearly needed. There
is also some evidence for a distinctively feminine moral
voice. According to Gilligan, whereas the typical male
moral voice speaks the language of justice, rights, and
rules, the female moral voice speaks a language of care
that emphasizes relationships and responsibilities [18].
These findings are controversial, but could explain the
gender effect observed.
Finally, while both cohorts represented North Ameri-
can investigators involved in neuroscience research, our
data also suggest that differing ethical issues may exist
for different subspecialties and present different barriers
to the consideration of ethics in the appropriate
research context.
We recognize the limitations of the study. Our
response rate was 19%. The sample was not random
and was limited to investigators holding government
grants in the United States. As well, responses likely
reflect the views of researchers with a pre-existing inter-
est in ethics. These characteristics limit the generaliz-
ability of our results to the broader community of
neuroscience researchers. We also acknowledge that
some of our survey questions were tailored to investiga-
tors who work with human subjects, and therefore may
not have been appropriate to our entire sample. In par-
ticular, investigators who work with animals identified
animal welfare as an additional ethical consideration, an
issue that we plan to address in future work. Finally, our
current work does not deliver a quantitative measure of
t h ed e g r e et ow h i c ht h ei s s u e sa n db a r r i e r si d e n t i f i e d
impact research. Future studies of larger cohorts and in-
depth interviews with researchers will serve to expand
our findings and will provide a more detailed ethical
landscape for neurodegeneration research.
Conclusion
While is it worthwhile to identify the barriers and the
motivators for the consideration of ethics in neu-
roscience research, it is equally important to propose
solution-oriented strategies to address the issues uncov-
ered. This is especially relevant in the face of the grow-
ing prevalence of age-associated neurodegenerative
diseases and the growing need for new approaches to
diagnose, treat and prevent these conditions. We agree
with Samarasekera [19] who, in a recent opinion piece,
encouraged the development of meaningful partnerships
between neuroscientists and ethicists. As junior scien-
tists today represent the investigators of tomorrow, it is
also essential to develop and integrate relevant ethics
curricula into graduate training [20]. Finally, the formal
ethics review process would greatly benefit from
enhanced communication channels between the
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the investigators themselves. Improved communication
between ethicists and neuroscientists beyond the institu-
tional review board requirements will lead to a better
understanding of the ethics needs of the research com-
munity and have a positive impact on research conduct,
public understanding of science and, ultimately, public
policy.
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